NPS Pharmaceuticals, Inc. Reports Four Additional Patients Achieve Independence from Parenteral Support in STEPS 2 Study of Gattex® in Adult Short Bowel Syndrome

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endoccrine disorders, today reported that four additional patients have successfully achieved independence from parenteral nutrition (PN) and intravenous (IV) fluids while on long-term Gattex® (teduglutide) therapy in STEPS 2, a 24-month open-label study in adult short bowel syndrome (SBS).